Brief: Median Technologies Completes Design Of Ibiopsy® Lung Cancer Screening Software

Median Technologies SA

22/03/2022 17:12

March 22 (Reuters) - Median Technologies SA  ALMDT.PA :
    * ANNOUNCES DESIGN COMPLETION OF ITS IBIOPSY® LUNG CANCER
SCREENING END-TO-END CADE/CADX SOFTWARE AS MEDICAL DEVICE (SAMD)
WITH OUTSTANDING SENSITIVITY & SPECIFICITY PERFORMANCE
    * IBIOPSY® LUNG CANCER SCREENING (LCS) CADE/CADX1OUTSTANDING
PERFORMANCE REACHES 94.7% SENSITIVITY2 AT 93.3% SPECIFICITY3,
BASED ON A COHORT OF 1,760 PATIENTS
    * HAS STARTED REGULATORY ENGAGEMENT AND DESIGN OF PIVOTAL
CLINICAL
STUDIES FOR IBIOPSY® LCS CADE/CADX SAMD, AND AIMS TO OBTAIN A US
FDA APPROVAL AND MARKET AUTHORIZATION BY END 2023

Source text for Eikon:  ID:nBw4t9HXsa 
Further company coverage:  ALMDT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))